Abstract
Cutaneous squamous cell carcinoma (cSCC) contributes to one of most common types of skin cancer. Epidermal growth factor receptor (EGFR) activation has been investigated to be associated with the development of cSCC. Lapatinib is an inhibitor targeting HER2/neu and EGFR pathway. We found that lapatinib can inhibit proliferation by enhancing apoptosis of human cSCC cell lines. The cSCC cell cycle distribution could be arrested in G2/M phase after lapatinib treatment. In the in vitro experiment, we found that lapatinib interrupted PI3K/AKT/mTOR signaling pathway in human cSCC cells. Furthermore, lapatinib could suppress epithelial to mesenchymal transition (EMT) via Wnt/ErK/PI3K-AKT signaling pathway to represent a promising anticancer drug for cSCC treatment.
Original language | English (US) |
---|---|
Pages (from-to) | 220-226 |
Number of pages | 7 |
Journal | Journal of Cancer |
Volume | 8 |
Issue number | 2 |
DOIs | |
State | Published - 2017 |
Externally published | Yes |
Keywords
- Cutaneous squamous cell carcinoma (cSCC)
- Epithelial to mesenchymal transition
- Lapatinib
- Proliferation
ASJC Scopus subject areas
- Oncology